NAGIOS: RODERIC FUNCIONANDO

WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture

dc.contributor.author	Aguirre Rueda, Diana
dc.contributor.author	Guerra Ojeda, Sol
dc.contributor.author	Aldasoro Celaya, Martín
dc.contributor.author	Iradi Casal, Antonio
dc.contributor.author	Obrador, Elena
dc.contributor.author	Mauricio Aviñó, María Dolores
dc.contributor.author	Vila Salinas, José María
dc.contributor.author	Marchio, Patricia
dc.contributor.author	Vallés Martí, Lilián Soraya
dc.date.accessioned	2016-01-08T12:42:52Z
dc.date.available	2016-01-08T12:42:52Z
dc.date.issued	2015
dc.identifier.citation	Aguirre Rueda, Diana; Guerra Ojeda, Sol; Aldasoro Celaya, Martín; Iradi, Antonio; Obrador, Elena; Mauricio, María Dolores; Vila, José María; Marchio, Patricia; Valles, Soraya L. (2015) WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture Plos One Apr 13 10(4)
dc.identifier.uri	http://hdl.handle.net/10550/49877
dc.description.abstract	Alzheimer´s disease (AD), a neurodegenerative illness involving synaptic dysfunction with extracellular accumulation of Aβ1-42 toxic peptide, glial activation, inflammatory response and oxidative stress, can lead to neuronal death. Endogenous cannabinoid system is implicated in physiological and physiopathological events in central nervous system (CNS), and changes in this system are related to many human diseases, including AD. However, studies on the effects of cannabinoids on astrocytes functions are scarce. In primary cultured astrocytes we studied cellular viability using MTT assay. Inflammatory and oxidative stress mediators were determined by ELISA and Westernblot techniques both in the presence and absence of Aβ1-42 peptide. Effects of WIN 55,212-2 (a synthetic cannabinoid) on cell viability, inflammatory mediators and oxidative stress were also determined. Aβ1-42 diminished astrocytes viability, increased TNF-α and IL-1β levels and p-65, COX-2 and iNOS protein expression while decreased PPAR-γ and antioxidant enzyme Cu/Zn SOD. WIN 55,212-2 pretreatment prevents all effects elicited by Aβ1-42. Furthermore, cannabinoid WIN 55,212-2 also increased cell viability and PPAR-γ expression in control astrocytes. In conclusion cannabinoid WIN 55,212-2 increases cell viability and anti-inflammatory response in cultured astrocytes. Moreover, WIN 55,212-2 increases expression of anti-oxidant Cu/Zn SOD and is able to prevent inflammation induced by Aβ1-42 in cultured astrocytes. Further studies would be needed to assess the possible beneficial effects of cannabinoids in Alzheimer's disease patients.
dc.language.iso	eng
dc.relation.ispartof	Plos One, 2015, vol. Apr 13, num. 10(4)
dc.subject	Neurologia
dc.subject	Fisiologia humana
dc.subject	Sistema nerviós Malalties
dc.title	WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture
dc.type	journal article	es_ES
dc.date.updated	2016-01-08T12:42:53Z
dc.identifier.idgrec	106094
dc.rights.accessRights	open access	es_ES